Survival Prolongation by Rationale Innovative Genomics
Status:
Active, not recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented
targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma
Kinase (ALK) translocation, ROS1 mutation if available or MET exon 14 skipping mutation if
available) will receive a tri-therapy associating avelumab, axitinib and palbociclib.